Extremely high infiltration of CD8+PD-L1+ cells detected in a stage III non-small cell lung cancer patient exhibiting hyperprogression during anti-PD-L1 immunotherapy after chemoradiation: A case report

Extremely high infiltration of CD8+PD-L1+ cells detected in a stage III non-small cell lung cancer patient exhibiting hyperprogression during anti-PD-L1 immunotherapy after chemoradiation: A case report

In recent years, immune checkpoint inhibitors (ICIs), represented by PD-1/PD-L1 monoclonal antibodies, have become a research hotspot in the field of oncology treatment. Immunotherapy has shown significant survival advantages in a variety of solid tumors. However, the phenomenon of hyperprogressive...

Full description

Bibliographic Details
Main Authors: Changshun Wu, Kai Zhou, Yan Zheng, Dongxiao Lv, Miaoqing Zhao, Yue Hu, Fei Qi, Xin Wang, Hong Feng
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
CD8+PD-L1+
hyperprogressive disease
PD-L1
durvalumab
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.969493/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.969493/full

Similar Items